A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database

During pre-approval clinical trials, the safety of axi-cel, a second-generation CAR-T-cell therapy directed against CD19, which dramatically improved the prognosis of intractable B-cell lymphomas, has been investigated only in about 400 patients. Therefore, additional information on this issue is ur...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafaniello, Concetta, Liguori, Valerio, Zinzi, Alessia, Gaio, Mario, Falco, Angela, Di Costanzo, Luigi, Gargano, Francesca, Trimarco, Valentina, Cataldi, Mauro, Capuano, Annalisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452324/
https://www.ncbi.nlm.nih.gov/pubmed/37626659
http://dx.doi.org/10.3390/biomedicines11082162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452324/
https://www.ncbi.nlm.nih.gov/pubmed/37626659
http://dx.doi.org/10.3390/biomedicines11082162

Ejemplares similares